Device Malfunctions Reported In Beta-Cath PMA Submission Not Significant
This article was originally published in The Gray Sheet
Executive Summary
A number of "minor device malfunctions" reported in Novoste's Beta-Cath radiation system premarket approval application do not detract from the device's efficacy, members of FDA's Circulatory System Devices Panel agreed Sept. 11.